Gemcitabin Medak powder for infusions 1000 mg. vial №1

Description

Gemcitabin Medak 1000 mg Composition

active substance: gemcitabine (in the form of gemcitabine hydrochloride) 1 ml of reconstituted solution for infusion contains 38 mg of gemcitabine (in the form of gemcitabine hydrochloride)
excipients: mannitol (E 421), sodium acetate trihydrate, hydrochloric acid, sodium hydroxide.

Gemcitabin Medak 1000 mg Dosage form

Powder for preparation of solution for infusion.

Gemcitabin Medak 1000 mg Pharmacological group

Antineoplastic medicines. Structural analogs of pyrimidine. ATC code L01B С05.

Indications

Bile duct cancer.

Bladder cancer. Gemcitabine Medak in combination with cisplatin is indicated for the treatment of patients with locally recurrent or metastatic bladder cancer.

Mammary cancer. Gemcitabine Medak in combination with paclitaxel is indicated for the treatment of patients with inoperable, locally recurrent or metastatic breast cancer after previous adjuvant / neoadjuvant chemotherapy. Anthracycline is prescribed before chemotherapy unless contraindicated.

Lung cancer is non-small cell. Gemcitabine Medak in combination with cisplatin is indicated as a first-line drug for the treatment of patients with locally progressive or metastatic non-small cell lung cancer. Gemcitabine Medak is indicated as monotherapy for the treatment of elderly patients and patients with performance status 2.

Ovarian cancer. Gemcitabine Medak in combination with carboplatin is indicated for the treatment of patients with locally progressive or metastatic epithelial ovarian carcinoma. Gemcitabine Medak is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma after a period of remission of at least 6 months, after previous therapy in the first line with platinum drugs.

Pancreas cancer. Gemcitabine Medak is indicated for the treatment of patients with locally progressive or metastatic adenocarcinomas of the pancreas.

Contraindications

Hypersensitivity to the drug.

Method of administration and dosage

Bile duct cancer.

Monotherapy.

Adults: the recommended dose of gemcitabine Medak is 1000 mg / m 2, which is administered intravenously over 30 minutes. The infusion is carried out once a week for three weeks in a row, then one week off. This 4 week cycle is repeated. The dose reduction with each cycle or during any one cycle may occur depending on the amount of toxicity to which the patient is exposed.

Combined use.

Adults Gemcitabine Medak in combination with cisplatin is recommended to use cisplatin 70 mg / m 2 on the 1st day of the cycle by infusion, then Gemcitabine Medak is administered at a dose of 1250 mg / m 2. Gemcitabine Medak is administered on the 1st and 8th days of each 21-day cycle by a 30-minute infusion. This 3 week cycle is repeated. A dose reduction with each cycle or within any one cycle may be applied depending on the degree of toxicity to which the patient is exposed.